03957nam 2200637 a 450 991081035720332120240417005619.00-309-21224-31-283-21345-197866132134570-309-21222-7(CKB)2550000000043073(EBL)3378800(SSID)ssj0000537170(PQKBManifestationID)11352570(PQKBTitleCode)TC0000537170(PQKBWorkID)10553842(PQKB)11052430(MiAaPQ)EBC3378800(Au-PeEL)EBL3378800(CaPaEBR)ebr10488621(CaONFJC)MIL321345(OCoLC)923283605(EXLCZ)99255000000004307320110827d2011 uy 0engurcn|||||||||txtccrGlutamate-related biomarkers in drug development for disorders of the nervous system workshop summary /Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board of Population Health and Public Health Practice, Institute of Medicine of the National Academies1st ed.Washington, D.C. National Academies Press20111 online resource (74 p.)Description based upon print version of record.0-309-21221-9 Includes bibliographical references and index.""Front Matter""; ""Reviewers""; ""Contents""; ""1 Introduction""; ""2 Overview of the Glutamatergic System""; ""3 Glutamate Biomarkers""; ""4 Treatment Implications of Biomarkers""; ""5 Challenges and Opportunities""; ""Appendix A: References""; ""Appendix B: Registered Attendees""; ""Appendix C: Agenda""Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.Glutamic acidPharmacokineticsCentral nervous systemDiseasesGlutamic acidPharmacokinetics.Central nervous systemDiseases.616.8061Pankevich Diana E1670810Davis Miriam856948Altevogt Bruce M1601278Institute of Medicine (U.S.).Forum on Neuroscience and Nervous System Disorders.Institute of Medicine (U.S.).Board of Population Health and Public Health Practice.MiAaPQMiAaPQMiAaPQBOOK9910810357203321Glutamate-related biomarkers in drug development for disorders of the nervous system4032898UNINA